Learn how Liv Hospital diagnoses Thalassemia using advanced genomic sequencing and non-invasive MRI T2* technology to prepare patients for curative stem cell therapy.
Send us all your questions or requests, and our expert team will assist you.
Diagnosis and Evaluation for Thalassemia
Diagnosing Thalassemia in the modern era requires far more than a simple blood test. It demands a comprehensive “Functional Staging” of the patient’s entire genetic and biological profile. At Liv Hospital, our evaluation process has two distinct goals. First, we must confirm the specific genetic mutation to understand the severity of the disease. Second, and perhaps more importantly, we must map the patient’s overall organ health to determine their eligibility for curative treatments like Stem Cell Transplantation.
For international patients, this evaluation is the critical turning point. It is the phase where we transition from observing symptoms to constructing a precise, personalized roadmap for a cure. By utilizing high-resolution genomic sequencing and non-invasive imaging technology, we can see the microscopic details of the blood and the hidden impact of iron overload on vital organs.
The diagnostic journey begins with a detailed analysis of the blood cells themselves. A Complete Blood Count gives us the initial clues. In Thalassemia patients, the red blood cells are typically smaller than normal and paler in color, a condition known as microcytic anemia. However, looking at the size of the cells is not enough to distinguish Thalassemia from common iron deficiency.
To confirm the diagnosis, we utilize High-Performance Liquid Chromatography. This advanced technology acts like a fingerprint scanner for the blood. It separates the hemoglobin into its different components, allowing us to measure the exact percentage of Hemoglobin A, which is the adult form, and Hemoglobin F, which is the fetal form. An elevated level of Hemoglobin F or the presence of abnormal Hemoglobin A2 provides a definitive biochemical signature of Beta Thalassemia. This step is crucial for differentiating between a “Silent Carrier” who requires no treatment and a patient with “Thalassemia Intermedia” or “Major” who needs medical intervention.
While blood tests show us the effects of the disease, Genomic Sequencing reveals the cause. This is the gold standard for diagnosis at Liv Hospital, especially for families considering stem cell therapy or gene editing.
We use molecular testing to read the DNA instructions of the HBA and HBB genes. This allows us to pinpoint the specific deletion or mutation responsible for the globin chain imbalance. Identifying the exact “break” in the DNA is vital because certain mutations respond better to specific treatment protocols. Furthermore, this genetic map is essential for Pre-implantation Genetic Diagnosis if the patient wishes to ensure that future children do not inherit the severe form of the disorder.
One of the most significant challenges in Thalassemia is the accumulation of iron in the body, known as iron overload. Historically, doctors had to perform painful liver biopsies to measure this toxicity. Today, we have replaced invasive procedures with advanced MRI T2 (T2-Star) technology*.
This specialized magnetic resonance imaging allows us to scan the liver and the heart to calculate the exact concentration of iron in milliseconds. The T2* scan is the most critical tool for risk stratification. It tells us if the heart is strong enough to withstand the conditioning chemotherapy used before a transplant. If the scan reveals high iron levels in the cardiac tissue, we initiate an aggressive “iron stripping” protocol to clean the organs and optimize the patient’s condition before moving forward with the transplant.
For patients seeking a cure through Stem Cell Transplantation, finding a matching donor is the most important step. We perform High-Resolution HLA Typing for the patient and their immediate family members. HLA markers are proteins on the surface of cells that tell the immune system which cells belong to the body and which are foreign.
The ideal scenario is finding a fully matched sibling. However, modern science has expanded the possibilities. If a sibling match is not available, we search the global bone marrow registries for an unrelated donor. Additionally, our center specializes in Haploidentical Transplants, which allow us to use a half-matched donor, such as a mother or father. This advanced protocol means that nearly every patient has a potential donor, removing one of the biggest barriers to a cure.
Before a stem cell transplant can occur, we must ensure the “soil” is ready for the “seed.” This involves a holistic evaluation of the patient’s physical resilience. Thalassemia is a systemic disease that affects the endocrine glands, bones, and heart, so our assessment covers all these bases.
We conduct a thorough endocrine evaluation to check the function of the thyroid, pancreas, and pituitary gland, which are often damaged by years of iron deposits. We also assess bone density to check for osteoporosis, a common side effect of marrow expansion. Finally, a comprehensive cardiac workup, including an echocardiogram and rhythm monitoring, ensures the heart is pumping efficiently. This rigorous “Functional Staging” allows us to tailor the intensity of the transplant conditioning to the specific needs of the patient, maximizing safety and success rates.
Send us all your questions or requests, and our expert team will assist you.
Hemoglobin electrophoresis looks at the proteins in the blood to see if they are abnormal. Genetic testing looks deeper at the DNA itself to find the specific mutation. Both are necessary for a complete diagnosis and treatment plan.
No. The T2* scan is completely non-invasive and painless. It involves lying still in the MRI machine for a short period. It does not use radiation and requires no needles or anesthesia, making it safe even for children.
Yes. We can perform prenatal testing using Chorionic Villus Sampling or Amniocentesis as early as the 11th week of pregnancy. This tests the DNA of the fetus to determine if they have inherited the severe form of the disease.
Testing the parents is essential to confirm the inheritance pattern and to identify potential donors. It also helps in counseling the family about the risks for future pregnancies.
HLA typing results for family members are usually available within a week. If we need to search the international registry for an unrelated donor, the process can take several weeks to a few months to find and confirm the best match.
Your Comparison List (you must select at least 2 packages)
